Ceramidase (CDase) hydrolyses the N-acyl linkage of the sphingolipid ceramide. We synthesized the non-fluorescent ceramide analogue (4E,2S,3R)-2-N-(10-pyrenedecanoyl)-1,3,17-trihydroxy-17-(3,5-dinitrobenzoyl)-4-heptadecene (10) that becomes fluorescent upon hydrolysis of its N-acyl bond. This novel substrate was used to study several kinetic aspects of the recombinant CDase from the pathogenic bacterium Pseudomonas aeruginosa PA01. Maximum CDase activity was observed above 1.5 microM substrate, with an apparent K(m) of 0.5+/-0.1 microM and a turnover of 5.5 min(-1). CDase activity depends on divalent cations without a strong specificity. CDase is inhibited by sphingosine and by several sphingosine analogues. The lack of inhibition by several mammalian CDase inhibitors such as D-erythro-MAPP, L-erythro-MAPP or N-oleoylethanolamine points to a novel active site and/or substrate binding region. The CDase assay described here offers the opportunity to develop and screen for specific bacterial CDase inhibitors of pharmaceutical interest.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0009-3084(01)00206-7DOI Listing

Publication Analysis

Top Keywords

ceramide analogue
8
pseudomonas aeruginosa
8
aeruginosa pa01
8
cdase
8
cdase activity
8
cdase inhibitors
8
synthesis novel
4
novel fluorescent
4
fluorescent ceramide
4
analogue characterization
4

Similar Publications

State of play in the molecular presentation and recognition of anti-tumor lipid-based analogues.

Front Immunol

December 2024

Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.

The Natural Killer T cells (NKT) are a unique subset of T lymphocytes that recognize lipid-based antigens that are presented by the monomorphic MHC-I-like molecule, CD1d. Over 30 years ago, the discovery of the glycolipid α-Galactosylceramide (α-GalCer) from the marine sponge , as a potent activator of the invariant Natural Killer T (iNKT) cells, has attracted great attention for its use in cancer immunotherapy. However, α-GalCer can initiate both pro-inflammatory T helper cell 1 (Th1) and anti-inflammatory Th2 type immune responses that can result in either enhanced or suppressed immunity in a somewhat unpredictable manner.

View Article and Find Full Text PDF

Sphingolipids, particularly sphingosine-1-phosphate (S1P), are bioactive lipids involved in regulating cellular processes such as proliferation, apoptosis, inflammation, and tumor progression. Alkaline ceramidase 2 (ACER2) plays a critical role in sphingolipid metabolism by catalyzing the hydrolysis of ceramide to sphingosine, which is subsequently converted to S1P. Dysregulation of ACER2 has been implicated in various gastrointestinal cancers, including colorectal cancer, gastric cancer, and hepatocellular carcinoma.

View Article and Find Full Text PDF

Gaucher disease (GD) is a lysosomal lipid storage disorder caused by β-glucocerebrosidase (encoded by gene) activity deficiency, resulting in the accumulation of glucosylceramide (Gb1) and its deacylated metabolite glucosylsphingosine (lyso-Gb1). Lyso-Gb1 has been studied previously and proved to be a sensitive biomarker, distinguishing patients with GD from carriers and healthy subjects. It was shown that its level corresponds with β-glucocerebrosidase activity, thus it remains unknown as to why carriers have slightly higher lyso-Gb1 level than healthy population.

View Article and Find Full Text PDF
Article Synopsis
  • This study investigates the metabolism of bioactive sphingolipids in bladder cancer, focusing on differences between non-muscle-invasive (NMIBC) and muscle-invasive (MIBC) tumors in 48 patients.
  • Results showed that MIBC tumors had increased levels of sphingosine-1-phosphate (S1P) and ceramide compared to healthy tissue and NMIBC tumors, indicating stage-dependent changes in sphingolipid metabolism.
  • The researchers suggest that the dysregulation of S1P metabolism may play a role in the progression of urothelial bladder cancer as it transitions from NMIBC to MIBC.
View Article and Find Full Text PDF
Article Synopsis
  • The study explores a glycolipid compound, C34, which activates NKT cells and shows promise for treating tumors but suffers from poor solubility.
  • Researchers formulated a PEGylated version of C34 (PLN-C34) to improve solubility and tested its effects in both mice and human cells, finding it maintains similar immune-stimulating properties as the original compound.
  • Results indicated that both C34 and PLN-C34 significantly extended survival in tumor-bearing mice and stimulated cytokine responses in human NKT cells, highlighting their potential for clinical use.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!